ClinicalTrials.gg
RecruitingNCT06507332Updated Jul 18, 2024

Combination Letrozole and Clomiphene Citrate Versus Letrozole Alone

An interventional study of Letrozole 2.5mg in Polycystic Ovary Syndrome, sponsored by Egymedicalpedia. Recruiting at 1 site in Egypt. Open to female participants aged 20 Years to 35 Years. Per ClinicalTrials.gov, last updated 2024-07-18.

Sponsored by Egymedicalpedia · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 2 months ago, but the record still lists the study as recruiting.
  • Registered 4 months after the study started (first participant enrolled Mar 2024, registered Jul 2024).
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
20 Years to 35 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing letrozole in Polycystic Ovary Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. Letrozole · Polycystic Ovary Syndrome.

Planned enrollment
21st of 26
64 · median 139
Started
2024
with 1 other
No phase
11 of 26
1 open now
Registered
22nd of 26
by date
Lead sponsor
2 of 26
Egymedicalpedia

Among the 26 studies testing letrozole in Polycystic Ovary Syndrome, this one is the 21st largest by planned enrollment, is one of 2 that started in 2024, is one of 11 with no phase, and was the 22nd registered.

Polycystic Ovary Syndrome

958 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.

Browse Polycystic Ovary Syndrome studies →

Open to participants now

1 of the 26 studies testing letrozole in Polycystic Ovary Syndrome is open now, in 1 country.

By country, each count listing its studies:

About letrozole

Letrozole: first FDA approval 1997 (FEMARA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 119 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 105 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.

This study: 20 Years to 35 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing letrozole in Polycystic Ovary Syndrome, or all of them as a file.
02

Study summary

Clomiphene citrate is a non-steroidal triphenylethylene derivative distantly related to diethylstilbestrol. It acts as a selective estrogen receptor modulator (SERM), similar to tamoxifen and raloxifene. All three drugs are competitive inhibitors of estrogen binding to estrogen receptors (ERs) and have mixed agonist and antagonist activity, depending upon the target tissue.

Letrozole is a potent, nonsteroidal, aromatase inhibitor, originally used for postmenopausal breast cancer therapy.

Read the detailed description

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in reproductive-age women and the most common cause of anovulatory infertility. The treatment of infertility in patients with PCOS focuses on ovulation induction. Many treatment regimens have been used, with varying success, to achieve ovulation, pregnancy, and live birth.

Clomiphene citrate (CC) is a commonly prescribed pharmacologic agent used to induce ovulation in women with PCOS. It works as a selective estrogen receptor modulator by competitively attaching to nuclear estrogen receptors. As the negative feedback of estrogen is reduced, secretion of gonadotropin hormones increases, inducing ovarian follicular growth.

Clomiphene citrate (CC) also has an anti-estrogenic effect on endometrial development and cervical mucus production,which has been suggested to contribute to a relatively low pregnancy rate despite a high ovulation rate.

Letrozole is another commonly used oral ovulation induction agent, with a different mechanism of action. It works as a highly selective aromatase inhibitor, preventing androgen-to-estrogen conversion. One proposed mechanism is via suppressed estrogen production resulting in decreased negative feedback on the hypothalamus and increased secretion of Follicular Stimulating Hormone (FSH). An additional proposed mechanism of improved ovulatory rates with the use of letrozole is increased follicular sensitivity to FSH resulting from temporarily increased intraovarian androgens .

Letrozole may offer a benefit over CC for ovulation induction because it does not block estrogen receptors in both central and peripheral target tissues, and normal central feedback mechanisms remain intact. The Pregnancy and Polycystic Ovary Syndrome (PPCOS) trial, a randomized controlled trial comparing letrozole and CC, demonstrated that letrozole was associated with a higher live birth rate (27.5% vs. 19.1%; P=007; rate ratio 1.44, 95% confidence interval [CI] 1.10-1.87) and cumulative ovulation rate (61.7% vs. 48.3%; P\<.001) among women with PCOS.

Other than letrozole or CC for ovulation induction, there are few treatment options available to PCOS patients except proceeding to gonadotropin injections or in vitro fertilization, both of which are associated with increased cost and risk.

03

Conditions studied

  • Polycystic Ovary Syndrome
04

Who can participate

Ages eligible
20 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of infertility, defined as the inability of couple to achieve a pregnancy after 12 months of regular timed unprotected intercourse in women \<35 years of age or after 6 months in women >35 years of age.
  • Diagnosis of PCOS based on the Rotterdam criteria, including two of the following three findings: oligomenorrhea or chronic anovulation, hyperandrogenism (clinical or laboratory), and polycystic ovary(ies) on ultrasound .
  • Normal HSG
  • Normal semen analysis.
  • Has capacity to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Unexplained infertility.
  • Other conditions that can cause chronic anovulation and androgen excess such as hyperthyroidism by thyroid profile.
  • congenital adrenal hyperplasia
  • Cushing
  • Untreated hyperprolactinemia.
  • Medical conditions not well controlled or to get pregnant with it like (uncontrolled diabetes mellitus, hypertension) .
  • endometrial hyperplasia/cancer
  • Allergy or contraindications to letrozole or CC. (by history)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (estimated)

Study arms

  • Active comparator
    Group 1 (Letrozole group)

    About 32 patients will receive letrozole 2.5 mg tablets only , once daily from the third date of the menses for 5 days for 3 successive periods

    Drug: Letrozole 2.5mg

  • Active comparator
    Group 2 (Letrozole and Clomiphene Citrate)

    About 32 patients will receive combined letrozole 2.5 mg tablets once daily and clomiphene citrate 50 mg tablets once daily from the third date of the menses for 5 days for 3 successive periods

    Drug: Letrozole 2.5mg

Interventions

  • to assess and compare the efficacy of Combination of letrozole and clomiphene citrate versus letrozole alone for ovulation induction in women with polycystic ovary syndrome (PCOS)

    Also known as: Clomiphene Citrate

06

What researchers measure

Primary outcomes

  1. Pregnancy Check

    The participants required to make pregnancy test after Receiving the drugs of the study

    Time frame: 2 weeks after ovulation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Sep 2024, 6 months after the start.

Of 218 interventional studies with no phase under Polycystic Ovary Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2024
First posted
Jul 18, 2024
StartActual
Mar 1, 2024
Primary completionEst.
Sep 1, 2024
CompletionEst.
Sep 10, 2024
Last update
Jul 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06507332
Lead sponsor
Egymedicalpedia
Responsible party
Sponsor
First posted
Jul 18, 2024
Start date
Mar 1, 2024
Primary completion
Sep 1, 2024 (estimated)
Completion
Sep 10, 2024 (estimated)
Last update
Jul 18, 2024

Study contacts

Mohamed Adel Mousa, MSC
Contact
sedyyasedy@gmail.com
+201093429998
Dina Yahia, Professor
study chair · Department of Obstetrics & Gynecology,Ain Shams University
Al Hassan Mohammad Khedr, Lecturer
study director · Department of Obstetrics & Gynecology,Ain Shams University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letrozole

Start the discussion